Slideshow

Key Concepts About Polypharmacy in Psychotic Disorders

Author(s):

Jose M. Rubio, MD

Clinicians should keep in mind the risk-to-benefit ratio considerations before initiating polypharmacy, especially if they have patients with prescriptions inherited from several sources. Here: A summary of recommendations about the use of polypharmacy in psychotic disorders.

Related Videos
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia
nicotine use
brain schizophrenia
schizophrenia
schizophrenia
exciting, brain
Related Content
FDA Committees Vote to Dismiss Clozapine REMS
November 20th 2024

FDA Committees Vote to Dismiss Clozapine REMS

Heidi Anne Duerr, MPH
Here's to a Psychedelic Revolution
April 9th 2022

Here's to a Psychedelic Revolution

Amir Inamdar MBBS, DNB (Psych), MFPM
schizophrenia
November 18th 2024

Long-Acting Injectables and a Team-Driven Approach for Schizophrenia Treatment

Tracy Hicks, DNP, FNP/PMHNP-BC
Treating ‘Morally Objectionable’ Patients
September 27th 2021

Treating ‘Morally Objectionable’ Patients

James L. Knoll IV, MD
metformin
November 11th 2024

“Happy Accidents”: Repurposing Metformin

Vania Modesto-Lowe, MD, MPH Roberto León-Barriera, MD Jasleen Kaur, MD
failed endpoint
November 11th 2024

Emraclidine for Schizophrenia Fails to Meet Primary Endpoints in Phase 2 EMPOWER Trials

Leah Kuntz
© 2024 MJH Life Sciences

All rights reserved.